MeSH term
Frequency | Condition_Probility | Animals | 43 | 0.0 |
Humans | 193 | 0.0 |
United States | 2 | 0.0 |
Base Sequence | 26 | 0.0 |
CHO Cells | 15 | 0.0 |
Cell Line | 12 | 0.0 |
DNA Damage | 18 | 2.0 |
*DNA Repair | 44 | 6.0 |
DNA-Binding Proteins/metabolism | 7 | 0.0 |
Hamsters | 20 | 0.0 |
Molecular Sequence Data | 31 | 0.0 |
Time Factors | 8 | 0.0 |
*DNA Damage | 23 | 3.0 |
*DNA Helicases | 19 | 8.0 |
DNA Repair/*genetics | 46 | 14.0 |
DNA-Binding Proteins/genetics | 14 | 1.0 |
Genotype | 52 | 0.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Mass Fragmentography | 2 | 0.0 |
Middle Aged | 68 | 0.0 |
Polymerase Chain Reaction | 25 | 0.0 |
*Polymorphism, Genetic | 56 | 1.0 |
Polymorphism, Restriction Fragment Length | 15 | 0.0 |
Proteins/genetics | 9 | 1.0 |
Smoking | 7 | 1.0 |
*Transcription Factors | 17 | 1.0 |
Comparative Study | 45 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 122 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Tumor Cells, Cultured | 8 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Female | 81 | 0.0 |
Male | 78 | 0.0 |
Risk | 7 | 0.0 |
Adolescent | 5 | 0.0 |
Adult | 52 | 0.0 |
Aged | 48 | 0.0 |
Case-Control Studies | 45 | 0.0 |
Codon | 7 | 1.0 |
DNA Repair/genetics | 8 | 4.0 |
DNA-Binding Proteins/*genetics | 65 | 3.0 |
Odds Ratio | 21 | 2.0 |
Risk Factors | 32 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
*Sister Chromatid Exchange | 2 | 6.0 |
Age Factors | 5 | 0.0 |
Alcohol Drinking | 2 | 1.0 |
Cohort Studies | 10 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 2 | 1.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Glutathione Transferase/genetics | 8 | 2.0 |
Occupational Exposure/*adverse effects | 3 | 3.0 |
Polymorphism, Genetic | 23 | 0.0 |
Prevalence | 2 | 0.0 |
Taiwan/epidemiology | 4 | 3.0 |
Cells, Cultured | 5 | 0.0 |
Cocarcinogenesis | 2 | 7.0 |
DNA Repair | 21 | 3.0 |
Genetic Predisposition to Disease | 16 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 67 | 0.0 |
Sunburn/*complications | 2 | 100.0 |
*Variation (Genetics) | 4 | 0.0 |
Alkylating Agents/pharmacology | 2 | 5.0 |
Blotting, Western | 8 | 0.0 |
Comet Assay | 4 | 5.0 |
DNA Ligases/metabolism | 4 | 12.0 |
DNA Polymerase beta/metabolism | 4 | 30.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*metabolism | 9 | 0.0 |
Dimerization | 6 | 0.0 |
Gene Deletion | 3 | 0.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Hela Cells | 13 | 0.0 |
Mice | 12 | 0.0 |
Mutation | 8 | 0.0 |
Protein Binding | 14 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Breast Neoplasms/epidemiology/*genetics | 2 | 1.0 |
Carbon-Oxygen Lyases/*genetics | 3 | 50.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
DNA-(Apurinic or Apyrimidinic Site) Lyase | 5 | 8.0 |
G2 Phase/genetics/radiation effects | 2 | 66.0 |
Radiation Tolerance/*genetics | 4 | 7.0 |
Risk Assessment | 12 | 1.0 |
Child | 4 | 0.0 |
Child, Preschool | 3 | 0.0 |
Glutathione Transferase/*genetics | 3 | 0.0 |
Prognosis | 7 | 0.0 |
Survival Rate | 5 | 0.0 |
Treatment Outcome | 5 | 0.0 |
Xenobiotics/metabolism | 2 | 4.0 |
Gene Frequency | 14 | 0.0 |
*Genetic Predisposition to Disease | 14 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 33 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Models, Molecular | 5 | 0.0 |
Mutation/genetics | 4 | 0.0 |
Protein Structure, Secondary | 4 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Exons | 6 | 0.0 |
Homozygote | 2 | 0.0 |
Phenotype | 5 | 0.0 |
Proteins/*genetics | 11 | 0.0 |
*Ultraviolet Rays | 4 | 1.0 |
Alleles | 19 | 0.0 |
Smoking/adverse effects/genetics | 2 | 20.0 |
Adenocarcinoma/genetics | 3 | 4.0 |
Carcinoma, Small Cell/genetics | 2 | 5.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
Confidence Intervals | 8 | 2.0 |
Smoking/adverse effects | 8 | 2.0 |
DNA Primers | 10 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Multivariate Analysis | 3 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Regression Analysis | 6 | 0.0 |
Cisplatin/pharmacology | 2 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Transfection | 7 | 0.0 |
*Cocarcinogenesis | 2 | 9.0 |
Dose-Response Relationship, Radiation | 5 | 1.0 |
In Vitro | 2 | 0.0 |
Radiation, Ionizing | 2 | 1.0 |
Transplantation, Heterologous | 2 | 0.0 |
Up-Regulation | 2 | 0.0 |
Disease Progression | 3 | 0.0 |
Incidence | 10 | 0.0 |
Logistic Models | 5 | 0.0 |
Lung Neoplasms/ethnology/*genetics | 3 | 60.0 |
Aged, 80 and over | 10 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Fluorouracil/administration & dosage | 2 | 1.0 |
Organoplatinum Compounds/administration & dosage | 2 | 18.0 |
Survival Analysis | 6 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Gene Expression | 4 | 0.0 |
English Abstract | 4 | 0.0 |
Environmental Exposure | 2 | 1.0 |
Genetic Markers | 3 | 0.0 |
Binding Sites | 6 | 0.0 |
Carbon-Oxygen Lyases/*metabolism | 2 | 10.0 |
Catalysis | 2 | 0.0 |
DNA/metabolism | 2 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Deoxyribonuclease IV (Phage T4-Induced) | 5 | 10.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Models, Biological | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Two-Hybrid System Techniques | 5 | 0.0 |
*Endonucleases | 3 | 3.0 |
Cell Survival/drug effects | 3 | 0.0 |
Ethyl Methanesulfonate/pharmacology | 2 | 12.0 |
Mitomycin/pharmacology | 2 | 2.0 |
X-Rays | 2 | 1.0 |
Drug Synergism | 2 | 0.0 |
Hydroxylamines/*pharmacology | 2 | 66.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 4 | 5.0 |
Carcinoma, Squamous Cell/genetics | 2 | 3.0 |
DNA Helicases/genetics | 3 | 14.0 |
Lung Neoplasms/*genetics | 6 | 2.0 |
Recombination, Genetic | 3 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
Cricetulus | 3 | 0.0 |
Genetic Complementation Test | 4 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
DNA Adducts/*blood | 2 | 18.0 |
Prospective Studies | 6 | 0.0 |
Apoptosis | 2 | 0.0 |
Cell Survival/radiation effects | 2 | 2.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
DNA, Complementary | 3 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 4 | 3.0 |
Protein Binding/genetics | 3 | 1.0 |
Recombinant Proteins/isolation & purification/metabolism | 3 | 2.0 |
Carcinoma, Squamous Cell/epidemiology/*genetics | 2 | 11.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
Glioma/*genetics | 2 | 2.0 |
Protein-Serine-Threonine Kinases/genetics | 2 | 1.0 |
Circular Dichroism | 4 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 2 | 1.0 |
Thermodynamics | 2 | 0.0 |
Tryptophan/genetics | 2 | 4.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
Environment | 2 | 2.0 |
Mitosis | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Models, Statistical | 2 | 1.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Breast Neoplasms/*epidemiology/*genetics | 2 | 5.0 |
Population Surveillance | 3 | 1.0 |
Reference Values | 5 | 0.0 |
Denmark | 2 | 1.0 |
Evolution, Molecular | 2 | 0.0 |
Haplotypes | 4 | 0.0 |
Linkage Disequilibrium | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Age Distribution | 6 | 1.0 |
Probability | 4 | 0.0 |
Sex Distribution | 4 | 1.0 |
Smoking/*adverse effects | 4 | 1.0 |
Lung Neoplasms/*epidemiology/*genetics | 2 | 22.0 |
United States/epidemiology | 2 | 0.0 |
DNA Repair/*physiology | 4 | 3.0 |
DNA, Single-Stranded/genetics/metabolism | 2 | 20.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Ligands | 2 | 0.0 |
Genetic Markers/genetics | 3 | 0.0 |
Glutamine/genetics | 2 | 4.0 |
*Genetic Markers | 3 | 0.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Mammals | 2 | 0.0 |
Sister Chromatid Exchange | 5 | 10.0 |
Escherichia coli | 2 | 0.0 |
Rats | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
DNA Repair/*genetics/radiation effects | 2 | 33.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Exons/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Ultraviolet Rays | 3 | 0.0 |
DNA/*metabolism | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Esophageal Neoplasms/epidemiology/*genetics/pathology | 2 | 50.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Smoking/*adverse effects/genetics | 2 | 14.0 |
Conserved Sequence/genetics | 2 | 1.0 |
DNA, Single-Stranded/*genetics | 2 | 28.0 |
Mutagenesis | 2 | 0.0 |
Genes, p53/*genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 8 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA Replication | 2 | 0.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
S Phase | 2 | 0.0 |
DNA/genetics/*metabolism | 2 | 2.0 |
DNA Damage/*genetics | 4 | 6.0 |
DNA Polymerase beta/*metabolism | 3 | 30.0 |
*DNA Repair/genetics | 2 | 14.0 |
Protein Conformation | 2 | 0.0 |
Glycophorin/*genetics | 2 | 7.0 |
*DNA Glycosylases | 2 | 2.0 |
DNA Repair/*drug effects | 2 | 6.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
Cell Line, Transformed | 2 | 0.0 |
DNA, Neoplasm/genetics | 3 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 5 | 0.0 |
DNA Ligases/genetics/*metabolism | 2 | 28.0 |
COS Cells | 2 | 0.0 |
Poly(ADP-ribose) Polymerases/*metabolism | 2 | 9.0 |
Zinc Fingers | 2 | 0.0 |
DNA-Binding Proteins/genetics/isolation & purification/*metabolism | 2 | 6.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Cosmids | 3 | 0.0 |
Alternative Splicing | 3 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
*Mutation | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Cell-Free System | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 2 | 0.0 |
DNA Ligases/*metabolism | 2 | 10.0 |
Organ Specificity | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Base Composition | 2 | 0.0 |
Guanine | 2 | 2.0 |
Substrate Specificity | 2 | 0.0 |
Questionnaires | 2 | 0.0 |
Registries | 2 | 0.0 |
Poland/epidemiology | 2 | 3.0 |
Apraxias/*genetics | 2 | 100.0 |
Arginine/genetics | 2 | 1.0 |
Japan | 2 | 0.0 |
*Smoking | 2 | 2.0 |
Cell Line, Tumor | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Finland/epidemiology | 2 | 1.0 |
Species Specificity | 2 | 0.0 |
Pilot Projects | 3 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
*Chromosomes, Human, Pair 19 | 4 | 1.0 |
Infant, Newborn | 2 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics | 2 | 11.0 |
DNA Glycosylases/*genetics | 2 | 28.0 |
Lung Neoplasms/etiology/*genetics | 2 | 7.0 |
China/epidemiology | 2 | 1.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Blotting, Southern | 5 | 0.0 |
DNA Probes | 2 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
DNA-Binding Proteins/*genetics/pharmacology | 2 | 50.0 |
*Occupational Exposure | 3 | 2.0 |
Radiation Injuries/*genetics | 2 | 66.0 |
*Genes | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Lymphocytes | 2 | 1.0 |
Neoplasms/genetics/physiopathology | 2 | 22.0 |
Linkage (Genetics) | 2 | 0.0 |
Aldehyde Dehydrogenase/*genetics | 2 | 1.0 |
Biotransformation | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
China | 2 | 0.0 |
*Genes, p53 | 3 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Enzymes/*genetics | 2 | 4.0 |
